Emergent BioSolutions Inc. (EBS) Earnings Call Analysis

NYSE · Healthcare · Drug Manufacturers - Specialty & Generic

12/25

Growth 2 Margin 1 Expansion 3 Platform 2 Financial 4

latest quarter score

Earnings Reports

12
Emergent BioSolutions (EBS) Q2 2026: Narcan Headwinds Drive $75M Revenue Guidance Cut, Cost Actions Accelerate
August 06, 2026
20
Emergent BioSolutions (EBS) Q1 2026: International MCM Revenue Climbs to 37%, Sharpening Margin Profile
May 01, 2026
14
EBS Q4 2025: Net Leverage Cut to 1.9x as Cash Flow Surges and Margin Expands
February 27, 2026
20
EBS Q3 2025: International MCM Sales Jump to 34%, Fueling Margin Expansion
October 29, 2025
20
Emergent BioSolutions (EBS) Q2 2025: Net Leverage Drops to 1.9x as MCM and Narcan Rebound
August 06, 2025
19
Emergent BioSolutions (EBS) Q1 2025: Net Leverage Cut to 2.8x as Turnaround Drives Margin Expansion
July 04, 2025
Emergent BioSolutions (EBS) Q4 2024: 518% Adjusted EBITDA Surge Highlights Turnaround Momentum Amid Revenue Pressure
March 04, 2025

Browse all companies